1. Scottish Study Group for the Care of Diabetes in
the Young. The incidence of childhood diabetes
in Scotland. 2006. 41st Annual Meeting of the
European Diabetes Epidemiology Group of the
EASD, Krakow, Poland, 20–23 May, 2006.
2. Wilson, IV, Gale, EAM, Bingley, PJ. The rising
incidence of childhood Type 1 diabetes in
the Oxford region 1985–2004. Diabet Med
2007;24(Suppl. 1):1–29.
3. Yorkshire & Humber Public Health Observatory.
PBS Diabetes Population Prevalence Model.
Yorkshire & Humber Public Health Observatory;
2005. URL: www.yhpho.org.uk/viewResource.
aspx?id=7 (accessed 26 December 2006).
4. Waugh N, Scotland G, McNamee P, Gillet M,
Brennan A, Goyder E, et al. Screening for type 2
diabetes: literature review and economic modelling.
Health Technol Assess 2007;11(17).
5. Yorkshire & Humber Public Health Observatory.
Diabetes Key Facts. 2006 URL: www.yhpho.org.
uk/diabetes_keyfacts.aspx (accessed 26 December
2006).
6. Turner R, Cull C, Holman R. United Kingdom
prospective diabetes study 17: a 9-year update
of a randomized, controlled trial on the effect of
improved metabolic control over complications in
non-insulin-dependent diabetes mellitus. Ann Intern
Med 1996;124:136–45.
7. UK Prospective Diabetes Study. U.K. prospective
diabetes study 16. Overview of 6 years’ therapy
of type II diabetes: a progressive disease. U.K.
Prospective Diabetes Study Group. [Erratum
appears in Diabetes 1996;45:1655.] Diabetes
1995;44:1249–58.
8. Wright A, Burden ACF, Paisey RB, Cull CA, Holman
RR. Sulfonylurea inadequacy: Efficacy of addition of
insulin over 6 years in patients with type 2 diabetes
in the U.K. Prospective Diabetes Study (UKPDS 57).
Diabetes Care 2002;25:330–6.
9. Donnan PT, Steinke DT, Newton RW, Morris AD,
Collaboration MEMO. Changes in treatment after
the start of oral hypoglycaemic therapy in type
2 diabetes: a population-based study. Diabet Med
2002;19:606–10.
10. Siebenhofer A, Plank J, Berghold A, Jeitler K,
Horvath K, Narath M, et al. Short acting insulin
analogues versus regular human insulin in patients
with diabetes mellitus. Cochrane Database Syst Rev
2006; Issue 2.
11. Colquitt J, Royle P, Waugh N. Are analogue insulins
better than soluble in continuous subcutaneous
insulin infusion? Results of a meta-analysis. Diabet
Med 2003;20:863–6.
12. National Institute for Health and Clinical
Excellence. Inhaled insulin for the treatment of type
1 and type 2 diabetes: Technology appraisal TA113.
25 January 2008. URL: www.nice.org.uk/Guidance/
TA113 (accessed 26 February 2009).
13. Diabetes Control and Complications Trial Research
Group. The effect of intensive treatment of diabetes
on the development and progression of longterm
complications in insulin-dependent diabetes
mellitus. N Engl J Med 1993;329:977–86.
14. Pickup JC, Keen H, Parsons JA, Alberti KG.
Continuous subcutaneous insulin infusion: an
approach to achieving normoglycaemia. Br Med J
1978;1:204–7.
15. Tamborlane WV, Sherwin RS, Genel M, Felig P.
Reduction to normal of plasma glucose in juvenile
diabetes by subcutaneous administration of insulin
with a portable infusion pump. N Engl J Med
1979;300:573–8.
16. Lenhard MJ, Reeves GD. Continuous subcutaneous
insulin infusion: a comprehensive review of insulin
pump therapy. Arch Int Med 2001;161:2293–300.
17. Pickup J, Keen H. Continuous subcutaneous
insulin infusion at 25 years: evidence base for the
expanding use of insulin pump therapy in type 1
diabetes. Diabetes Care 2002;25:593–8.
18. Pickup J, Mattock M, Kerry S. Glycaemic control
with continuous subcutaneous insulin infusion
compared with intensive insulin injections in
patients with type 1 diabetes: meta-analysis of
randomised controlled trials. BMJ 2002;324:705.
19. Côté B, St-Hilaire C. Comparison of the insulin
pump and multiple daily insulin injections in
intensive therapy for type 1 diabetes. Montreal, PQ,
Canada: Agence d’évaluation des technologies et
des modes d’intervention en santé (AETMIS); 2005.
20. Graff MR, Rubin RR, Walker EA. How diabetes
specialists treat their own diabetes: findings from a
study of the AADE and ADA membership. Diabetes
Educ 2000;26:460–7.
21. Pickup J, Keen H. Continuous subcutaneous insulin
infusion in type 1 diabetes: is beneficial in selected
patients and should be more widely available. BMJ
2001;322:1262–3.
22. Dunger DB, Sperling MA, Acerini CL, Bohn DJ,
Daneman D, Danne TPA, et al. ESPE/LWPES
consensus statement on diabetic ketoacidosis
in children and adolescents. Arch Dis Child
2004;89:188–94.
23. Ganesh R, Suresh N, Ramesh J. Diabetic
ketoacidosis in children. Nat Med J India
2006;19:155–8.
24. Henriksen OM, Roder ME, Prahl JB, Svendsen OL.
Diabetic ketoacidosis in Denmark Incidence and
mortality estimated from public health registries.
Diabetes Res Clin Pract 2007;76:51–6.
25. Cryer PE. Hypoglycemia in diabetes:
pathophysiological mechanisms and diurnal
variation. Prog Brain Res 2006;153:361–5.
26. Ghafour IM, Allan D, Foulds WS. Common causes
of blindness and visual handicap in the west of
Scotland. Br J Ophthalmol 1983;67:209–13.
27. NHS Scotland. The Scottish Renal Registry Report
2002–2004. Edinburgh: ISD Scotland Publications;
2007.
28. Laing SP, Swerdlow AJ, Slater SD, Botha JL,
Burden AC, Waugh NR, et al. The British Diabetic
Association Cohort Study, II: Cause-specific
mortality in patients with insulin-treated diabetes
mellitus. Diabet Med 1999;16:466–71.
29. Laing SP, Swerdlow AJ, Slater SD, Burden AC,
Morris A, Waugh NR, et al. Mortality from heart
disease in a cohort of 23,000 patients with insulintreated
diabetes. Diabetologia 2003;46:760–5.
30. Selvin E, Marinopoulos S, Berkenblit G, Rami
T, Brancati FL, Powe NR, et al. Meta-analysis:
glycosylated hemoglobin and cardiovascular disease
in diabetes mellitus. Ann Intern Med 2004;141:421.
31. Stettler C, Allemann S, Juni P, Cull CA, Holman
RR, Egger M, et al. Glycemic control and
macrovascular disease in types 1 and 2 diabetes
mellitus: Meta-analysis of randomized trials. Am
Heart J 2006;152:27–38.
32. Boulton AJ, Vileikyte L, Ragnarson-Tennvall G,
Apelqvist J. The global burden of diabetic foot
disease. Lancet 2005;366:1719–24.
33. Currie CJ, Morgan CL, Peters JR. The
epidemiology and cost of inpatient care for
peripheral vascular disease, infection, neuropathy,
and ulceration in diabetes. Diabetes Care
1998;21:42–8.
34. Wang PH, Lau J, Chalmers TC. Meta-analysis of
the effects of intensive glycemic control on late
complications of type I diabetes mellitus. Online J
Curr Clin Trials 1993;Doc No 60:5023.
35. Shamoon H, Duffy H, Fleischer N, Engel S, Saenger
P, Strelyzn M, et al. The effect of intensive diabetes
treatment on the progression of diabetic retinopathy
in insulin-dependent diabetes mellitus: the diabetes
control and complications trial. Arch Ophthalmol
1995;113:36–51.
36. Diabetes Control and Complications Trial Research
Group. The absence of a glycemic threshold for
the development of long-term complications:
the perspective of the Diabetes Control and
Complications Trial. Diabetes 1996;45:1289–98.
37. Genuth S, Lipps J, Lorenzi G, Nathan DM, Davis
MD, Lachin JM, et al. Effect of intensive therapy on
the microvascular complications of type 1 diabetes
mellitus. JAMA 2002;287:2563–9.
38. Writing Team for the Diabetes Control and
Complications Trial. Epidemiology of Diabetes
Interventions and Complications Research Group.
Sustained effect of intensive treatment of type 1
diabetes mellitus on development and progression
of diabetic nephropathy: the Epidemiology of
Diabetes Interventions and Complications (EDIC)
study. JAMA 2003;290:2159–67.
39. Nathan DM, Cleary PA, Backlund JY, Genuth SM,
Lachin JM, Orchard TJ, et al. Intensive diabetes
treatment and cardiovascular disease in patients
with type 1 diabetes. N Engl J Med 2005;353:2643–
53.
40. Ihnat MA, Thorpe JE, Ceriello A. Hypothesis: The
‘metabolic memory’, the new challenge of diabetes.
Diabet Med 2007;24:582–6.
41. Svoren BM, Volkening LK, Butler DA, Moreland
EC, Anderson BJ, Laffel LM. Temporal trends
in the treatment of pediatric type 1 diabetes and
impact on acute outcomes. J Pediatr 2007;150:279–
85.
42. Scottish Study Group for the Care of the Young
Diabetic. Factors influencing glycemic control in
young people with type 1 diabetes in Scotland: a
population-based study (DIABAUD2). Diabetes Care
2001;24:239–44.
43. Scottish Study Group for the Care of the Young
with Diabetes. A longitudinal observational study of insulin therapy and glycaemic control in Scottish
children with type 1 diabetes: DIABAUD 3. Diabet
Med 2006;23:1216–21.
44. Diabetes UK. Diabetes: State of the Nations
2006. URL: www.diabetes.org.uk/Professionals/
Information_resources/Reports/Diabetes_State_of_
the_Nations_2006/(accessed 24 May 2007).
45. Hayward RA, Manning WG, Kaplan SH, Wagner
EH, Greenfield S. Starting insulin therapy in
patients with type 2 diabetes: effectiveness,
complications, and resource utilization. [Erratum
appears in JAMA 1999;281:1989.] JAMA
1997;278:1663–9.
46. Yki-Jarvinen H, Ryysy L, Kauppila M, Kujansuu
E, Lahti J, Marjanen T, et al. Effect of obesity on
the response to insulin therapy in non insulindependent
diabetes mellitus. J Clin Endocrinol Metab
1997;82:4037–43.
47. Calvert MJ, McManus RJ, Freemantle N.
Management of type 2 diabetes with multiple
oral hypoglycaemic agents or insulin in primary
care: retrospective cohort study. Br J Gen Pract
2007;57:455–60.
48. Gulliford MC, Ashworth M, Robotham D, Mohiddin
A. Achievement of metabolic targets for diabetes by
English primary care practices under a new system
of incentives. Diabet Med 2007;24:505–11.
49. Diabetes Control and Complications Trial Research
Group. Hypoglycemia in the diabetes control and
complications trial. Diabetes 1997;46:271–86.
50. Colquitt JL, Green C, Sidhu MK, Hartwell D,
Waugh N. Clinical and cost-effectiveness of
continuous subcutaneous insulin infusion for
diabetes. Health Technol Assess 2004;8(43).
51. National Institute for Health and Clinical
Excellence. Guidance on the use of long-acting
insulin analogues for the treatment of diabetes:
insulin glargine. Technology Appraisal 53, 2002.
http://guidance.nice.org.uk/TA53/guidance/pdf/
English (accessed 26 February 2009).
52. Hepburn DA, Frier BM. Hypoglycaemia and
diabetes. In Lawson DH, Toft AD, editors. Current
medicine. Edinburgh: Churchill Livingstone; 1994.
53. Nordfeldt S, Ludvigsson J. Fear and other
disturbances of severe hypoglycaemia in children
and adolescents with type 1 diabetes mellitus. J
Pediatr Endocrinol Metab 2005;18:83–91.
54. Clarke WL, Gonder-Frederick A, Snyder AL, Cox
DJ. Maternal fear of hypoglycemia in their children
with insulin dependent diabetes mellitus. J Pediatr
Endocrinol 1998;11(Suppl. 1):189–94.
55. Streisand R, Swift E, Wickmark T, Chen R, Holmes
CS. Pediatric parenting stress among parents of
children with type 1 diabetes: the role of selfefficacy,
responsibility, and fear. J Pediatr Psychol
2005;30:513–21.
56. Heller S. How should hypoglycaemia unawareness
be managed. In Gill G, Pickup J, Williams G,
editors. Difficult diabetes. Oxford: Blackwell Science;
2001.
57. Warren RE, Frier BM. Hypoglycaemia and cognitive
function. Diabetes Obes Metab 2005;7:493–503.
58. Jacobson AM, Musen G, Ryan CM, Silvers N, Cleary
P, Waberski B, et al. Long-term effect of diabetes and
its treatment on cognitive function. N Engl J Med
2007;356:1842–52.
59. Gold AE, Frier BM. Hypoglycemia: practical
and clinical implications. In Kelnar CJH, editor.
Childhood and adolescent diabetes. London: Chapman
& Hall; 1995.
60. McCarthy AM, Lindgren S, Mengeling MA,
Tsalikian E, Engvall J. Factors associated with
academic achievement in children with type 1
diabetes. Diabetes Care 2003;26:112–17.
61. Northam EA, Anderson PJ, Jacobs R, Hughes M,
Warne GL, Werther GA. Neuropsychological profiles
of children with type 1 diabetes 6 years after disease
onset. Diabetes Care 2001;24:1541–6.
62. Dahlquist G, Kallen B. School performance in
children with type 1 diabetes: a population-based
register study. Diabetologia 2007;50:957–64.
63. Desrocher M, Rovet J. Neurocognitive correlates
of type 1 diabetes mellitus in childhood. Child
Neuropsychol 2004;10:36–52.
64. Ferguson SC, Blane A, Wardlaw J, Frier BM, Perros
P, McCrimmon RJ, et al. Influence of an early-onset
age of type 1 diabetes on cerebral structure and
cognitive function. Diabetes Care 2005;28:1431–7.
65. Hershey T, Perantie DC, Warren SL, Zimmerman
EC, Sadler M, White NH. Frequency and timing
of severe hypoglycemia affects spatial memory
in children with type 1 diabetes. Diabetes Care
2005;28:2372–7.
66. Wysocki T, Harris MA, Mauras N, Fox L, Taylor
A, Jackson SC, et al. Absence of adverse effects
of severe hypoglycemia on cognitive function in
school-aged children with diabetes over 18 months.
Diabetes Care 2003;26:1100–5.
67. Leese GP, Wang J, Broomhall J, Kelly P, Marsden A,
Morrison W, et al. Frequency of severe hypoglycemia
requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service
resource use. Diabetes Care 2003;26:1176–80.
68. Donnelly LA, Morris AD, Frier BM, Ellis JD,
Donnan PT, Durrant R, et al. Frequency and
predictors of hypoglycaemia in type 1 and insulintreated
type 2 diabetes: a population-based study.
Diabet Med 2005;22:749–55.
69. Heller SR, Choudhary P, Davies C, Emery
C, Campbell MJ, Freeman J, et al. Risk of
hypoglycaemia in types 1 and 2 diabetes: Effects of
treatment modalities and their duration. Diabetologia
2007;50:1140–7.
70. Bolli GB, Gerich JE. The ‘dawn phenomenon’: a
common occurrence in both non-insulin-dependent
and insulin-dependent diabetes mellitus. N Engl J
Med 1984;310:746–50.
71. Pickup JC. Is insulin pump treatment justifiable?
In Gill G, Pickup JC, Williams G, editors. Difficult
diabetes. Oxford: Blackwell Science; 2001.
72. Kanc K, Janssen MM, Keulen ET, Jacobs MA, Popp-
Snijders C, Snoek FJ, et al. Substitution of nighttime
continuous subcutaneous insulin infusion
therapy for bedtime NPH insulin in a multiple
injection regimen improves counterregulatory
hormonal responses and warning symptoms of
hypoglycaemia in IDDM. Diabetologia 1998;41:
322–9.
73. DAFNE. Dose Adjustment For Normal Eating
(DAFNE) website, 2009. URL: www.dafne.uk.com/
(accessed 26 February 2009).
74. National Institute for Clinical Excellence. Guidance
on the use of continuous subcutaneous insulin
infusion: Technology Appraisal No. 57, 2003.
URL: www.nice.org.uk/guidance/TA57/ (accessed 26
February 2009).
75. Warren E, Weatherley-Jones E, Chilcott J, Beverley
C. Systematic review and economic evaluation of
a long-acting insulin analogue, insulin glargine.
Health Technol Assess 2004;8(45).
76. Ashwell SG, Amiel SA, Bilous RW, Dashora U,
Heller SR, Hepburn DA, et al. Improved glycaemic
control with insulin glargine plus insulin lispro: a
multicentre, randomized, cross-over trial in people
with Type 1 diabetes. Diabet Med 2006;23:285–92.
77. Chatterjee S, Jarvis-Kay J, Rengarajan T,
Lawrence IG, McNally PG, Davies MJ. Glargine
versus NPH insulin: efficacy in comparison with
insulin aspart in a basal bolus regimen in type 1
diabetes: the glargine and aspart study (GLASS) a
randomised cross-over study. Diabetes Res Clin Pract
2007;77:215–22.
78. De L, I, Vague P, Selam JL, Skeie S, Lang H,
Draeger E, et al. Insulin detemir used in basal-bolus
therapy in people with type 1 diabetes is associated
with a lower risk of nocturnal hypoglycaemia and
less weight gain over 12 months in comparison to
NPH insulin. Diabetes Obes Metab 2005;7:73–82.
79. Dixon B, Peter CH, Burdick J, Fiallo-Scharer R,
Walravens P, Klingensmith G, et al. Use of insulin
glargine in children under age 6 with type 1
diabetes. Pediatric Diabetes 2005;6:150–4.
80. Fulcher GR, Gilbert RE, Yue DK. Glargine is
superior to neutral protamine Hagedorn for
improving glycated haemoglobin and fasting blood
glucose levels during intensive insulin therapy.
Intern Med J 2005;35:536–42.
81. Hermansen K, Fontaine P, Kukolja KK, Peterkova
V, Leth G, Gall MA. Insulin analogues (insulin
detemir and insulin aspart) versus traditional
human insulins (NPH insulin and regular human
insulin) in basal-bolus therapy for patients with type
1 diabetes. Diabetologia 2004;47:622–9.
82. Hershon KS, Blevins TC, Blevins TC, Blevins TC.
Once-daily insulin glargine compared with twicedaily
NPH insulin in patients with type 1 diabetes.
Endocr Pract 2004;10:10–17.
83. Home P, Bartley P, Russell-Jones D, Hanaire-Broutin
H, Heeg JE, Abrams P, et al. Insulin detemir offers
improved glycemic control compared with NPH
insulin in people with type 1 diabetes: a randomized
clinical trial. Diabetes Care 2004;27:1081–7.
84. Home PD, Rosskamp R, Forjanic-Klapproth J,
Dressler A, European Insulin Glargine Study Group.
A randomized multicentre trial of insulin glargine
compared with NPH insulin in people with type 1
diabetes. Diabetes Metab Res Rev 2005;21:545–53.
85. Kudva YC, Basu A, Jenkins GD, Pons GM, Quandt
LL, Gebel JA, et al. Randomized controlled
clinical trial of glargine versus ultralente insulin
in the treatment of type 1 diabetes. Diabetes Care
2005;28:10–14.
86. Murphy NP, Keane SM, Ong KK, Ford-Adams M,
Edge JA, Acerini CL, et al. Randomized cross-over
trial of insulin glargine plus lispro or NPH insulin
plus regular human insulin in adolescents with type
1 diabetes on intensive insulin regimens. Diabetes
Care 2003;26:799–804.
87. Pieber TR, Draeger E, Kristensen A, Grill V.
Comparison of three multiple injection regimens
for type 1 diabetes: morning plus dinner or bedtime
administration of insulin detemir vs. morning plus bedtime NPH insulin. Diabet Med 2005;22:850–7.
88. Porcellati F, Rossetti P, Pampanelli S, Fanelli
CG, Torlone E, Scionti L, et al. Better long-term
glycaemic control with the basal insulin glargine as
compared with NPH in patients with type 1 diabetes
mellitus given meal-time lispro insulin. Diabet Med
2004;21:1213–20.
89. Russell-Jones D, Simpson R, Hylleberg B, Draeger
E, Bolinder J. Effects of QD insulin detemir or
neutral protamine Hagedorn on blood glucose
control in patients with type I diabetes mellitus
using a basal-bolus regimen. Clin Ther 2004;26:
724–36.
90. Schober E, Schoenle E, Van Dyk J, Wernicke-Panten
K, Pediatric Study Group of Insulin Glargine.
Comparative trial between insulin glargine and
NPH insulin in children and adolescents with type 1
diabetes mellitus. J Pediatr Endocrinol 2002;15:
369–76.
91. Standl E, Lang H, Roberts A. The 12-month efficacy
and safety of insulin detemir and NPH insulin in
basal-bolus therapy for the treatment of type 1
diabetes. Diabetes Technol Ther 2004;6:579–88.
92. Vague P, Selam JL, Skeie S, De L, I, Elte JW, Haahr
H, et al. Insulin detemir is associated with more
predictable glycemic control and reduced risk of
hypoglycemia than NPH insulin in patients with
type 1 diabetes on a basal-bolus regimen with
premeal insulin aspart. Diabetes Care 2003;26:590–6.
93. Mathieu C. Can we reduce hypoglycaemia with
insulin detemir? International Journal of Obesity &
Related Metabolic Disorders 2004;28:S35–40.
94. Peterson GE. Intermediate and long-acting insulins:
a review of NPH insulin, insulin glargine and
insulin detemir. Curr Med Res Opin 2006;22:2613–
19.
95. Bangstad HJ, Danne T, Deeb LC, Jarosz-Chobot
P, Urakami T, Hanas R. Insulin treatment. Pediatr
Diabetes 2007;8:88–102.
96. Palmer AJ, Roze S, Valentine WJ, Smith I, Wittrup-
Jensen KU. Cost-effectiveness of detemir-based
basal/bolus therapy versus NPH-based basal/bolus
therapy for type 1 diabetes in a UK setting: an
economic analysis based on meta-analysis results of
four clinical trials. Curr Med Res Opin 2004;20:1729–
46.
97. Valentine WJ, Palmer AJ, Erny-Albrecht KM, Ray
JA, Cobden D, Foos V, et al. Cost-effectiveness of
basal insulin from a US health system perspective:
comparative analyses of detemir, glargine, and
NPH. Adv Ther 2006;23:191–207.
98. Horvath K, Jeitler K, Berghold A, Ebrahim SH,
Gratzer TW, Plank J, et al. Long-acting insulin
analogues versus NPH insulin (human isophane
insulin) for type 2 diabetes mellitus. Cochrane
Database Syst Rev 2007.
99. Boland EA, Grey M, Oesterle A, Fredrickson
L, Tamborlane WV. Continuous subcutaneous
insulin infusion. A new way to lower risk of severe
hypoglycemia, improve metabolic control, and
enhance coping in adolescents with type 1 diabetes.
Diabetes Care 1999;22:1779–84.
100. Mack-Fogg J, Bates S, Faro B, Sciera M, Ippolito
K, Orlowski CC, et al. Safe and effective use of
continuous subcutaneous insulin infusion in young
children with type 1 diabetes mellitus. Pediatr Res
2002;51:122A.
101. Rudolph JW, Hirsch IB. Assessment of therapy with
continuous subcutaneous insulin infusion in an
academic diabetes clinic. Endocr Pract 2002;8:401–5.
102. Haardt MJ, Berne C, Dorange C, Slama G, Selam
J-L. Efficacy and indications of CSII revisited: The
Hotel-Dieu cohort. Diabet Med 1997;14:407–8.
103. Bending JJ, Pickup JC, Keen H. Frequency of
diabetic ketoacidosis and hypoglycemic coma
during treatment with continuous subcutaneous
insulin infusion. Audit of medical care. Am J Med
1985;79:685–91.
104. Chantelau E, Spraul M, Muhlhauser I, Gause R,
Berger M. Long-term safety, efficacy and sideeffects
of continuous subcutaneous insulin infusion
treatment for type 1 (insulin-dependent) diabetes
mellitus: a one centre experience. Diabetologia
1989;32:421–6.
105. Raskin P. Treatment of type-I diabetes with portable
insulin infusion devices. Diabetes Care 1982;5:48–52.
106. Department of Health. Insulin pump services:
Report of the Insulin Pumps Working Group, 2007.
URL: www.dh.gov.uk/en/Publicationsandstatistics/
Publications/PublicationsPolicyAndGuidance/
DH_072777 (accessed 26 February 2009).
107. Pickup JC, Sutton AJ. Severe hypoglycaemia and
glycaemic control in type 1 diabetes: meta-analysis
of multiple daily insulin injections compared with
continuous subcutaneous insulin infusion. Diabet
Med 2008;25:765–74.
108. Barnard KD, Lloyd CE, Skinner TC. Systematic
literature review: quality of life associated with
insulin pump use in type 1 diabetes. Diabet Med
2007;24:607–17.
109. Khan KS, ter Riet G, Glanville J, Sowden A,
Kleijnen J. Undertaking systematic reviews of
research on effectiveness: CRD’s guidance for those carrying out and commissioning reviews. CRD
Report 4 (2nd edn); 2001.
110. Doyle EA, Weinzimer SA, Steffen AT, Ahern
JA, Vincent M, Tamborlane WV. A randomized,
prospective trial comparing the efficacy of
continuous subcutaneous insulin infusion with
multiple daily injections using insulin glargine.
Diabetes Care 2004;27:1554–8.
111. Thomas RM, Aldibbiat A, Griffin W, Cox MA, Leech
NJ, Shaw JA. A randomized pilot study in type 1
diabetes complicated by severe hypoglycaemia,
comparing rigorous hypoglycaemia avoidance with
insulin analogue therapy, CSII or education alone.
Diabet Med 2007;24:778–83.
112. Maran A, Crazzolara D, Nicoletti M, Costa S, dal
Pos M, Tiengo A, et al. A randomized crossover
study to compare continuous subcutaneous insulin
infusion (CSII) with multiple daily injection (MDI)
in type 1 diabetic patients previously treated with
CSII. Diabetologia 2005;48:A328.
113. Bolli GB, Capani F, Home PD, Kerr D, Thomas
R, Torlone E, et al. Comparison of a multiple daily
injection regimen with once-daily insulin glargine
basal insulin and mealtime lispro, to continuous
subcutaneous insulin infusion: a randomised, open,
parallel study. Diabetes 2004;53:A107–8.
114. Berthe E, Lireux B, Coffin C, Goulet-Salmon
B, Houlbert D, Boutreux S, et al. Effectiveness
of intensive insulin therapy by multiple daily
injections and continuous subcutaneous infusion:
a comparison study in type 2 diabetes with
conventional insulin regimen failure. Horm Metab
Res 2007;39:224–9.
115. Herman WH, Ilag LL, Johnson SL, Martin CL,
Sinding J, Al Harthi A, et al. A clinical trial of
continuous subcutaneous insulin infusion versus
multiple daily injections in older adults with type 2
diabetes. Diabetes Care 2005;28:1568–73.
116. Raskin P, Bode BW, Marks JB, Hirsch IB, Weinstein
RL, McGill JB, et al. Continuous subcutaneous
insulin infusion and multiple daily injection
therapy are equally effective in type 2 diabetes: a
randomized, parallel-group, 24-week study. Diabetes
Care 2003;26:2598–603.
117. Wainstein J, Metzger M, Boaz M, Minuchin O,
Cohen Y, Yaffe A, et al. Insulin pump therapy vs.
multiple daily injections in obese type 2 diabetic
patients. Diabet Med 2005;22:1037–46.
118. Cohen D, Weintrob N, Benzaquen H, Galatzer A,
Fayman G, Phillip M. Continuous subcutaneous
insulin infusion versus multiple daily injections
in adolescents with type I diabetes mellitus: a
randomized open crossover trial. J Pediatr Endocrinol
2003;16:1047–50.
119. DeVries JH, Snoek FJ, Kostense PJ, Masurel N,
Heine RJ, Dutch Insulin Pump Study Group. A
randomized trial of continuous subcutaneous
insulin infusion and intensive injection therapy in
type 1 diabetes for patients with long-standing poor
glycemic control. Diabetes Care 2002;25:2074–80.
120. Dimeglio LA, Pottorff TM, Boyd SR, France L,
Fineberg N, Eugster EA. A randomized, controlled
study of insulin pump therapy in diabetic
preschoolers. J Pediatr 2004;145:380–4.
121. Fox LA, Buckloh LM, Smith SD, Wysocki T, Mauras
N. A randomized controlled trial of insulin pump
therapy in young children with type 1 diabetes.
Diabetes Care 2005;28:1277–81.
122. Hoogma RP, Hoekstra JB, Michels BP, Levi M.
Comparison between multiple daily insulin injection
therapy (MDI) and continuous subcutaneous
insulin infusion therapy (CSII), results of the five
nations study. Diabetes Res Clin Pract 2006;74(Suppl.
2):S144–7.
123. Pozzilli P, Crino A, Schiaffini R, Manfrini S,
Fioriti E, Coppolino G, et al. A 2-year pilot trial of
continuous subcutaneous insulin infusion versus
intensive insulin therapy in patients with newly
diagnosed type 1 diabetes (IMDIAB 8). Diabetes
Technol Ther 2003;5:965–74.
124. Weintrob N, Schechter A, Benzaquen H, Shalitin
S, Lilos P, Galatzer A, et al. Glycemic patterns
detected by continuous subcutaneous glucose
sensing in children and adolescents with type 1
diabetes mellitus treated by multiple daily injections
vs continuous subcutaneous insulin infusion. Arch
Pediatr Adolesc Med 2004;158:677–84.
125. Weintrob N, Schechter A, Bezaquen H, Shalitin S,
Lilos P, Galatzer A, et al. Glycemic patterns detected
by continuous subcutaneous glucose sensing in
children with type 1 diabetes treated by MDI or
CSII. Diabetes 2003;52:A100.
126. Wilson DM, Buckingham BA, Kunselman EL,
Sullivan MM, Paguntalan HU, Gitelman SE. A
two-center randomized controlled feasibility trial
of insulin pump therapy in young children with
diabetes. Diabetes Care 2005;28:15–19.
127. Department of Health. National service framework for
diabetes: standards. London: Department of Health;
2001.
128. Scottish Intercollegiate Guidelines Network.
Management of diabetes. SIGN Publication No. 55.
Edinburgh: Scottish Intercollegiate Guidelines
Network; 2001.
129. Casson IF, Clarke CA, Howard CV, McKendrick
O, Pennycook S, Pharoah PO, et al. Outcomes of
pregnancy in insulin dependent diabetic women:
results of a five year population cohort study. BMJ
1997;315:275–8.
130. Hawthorne G, Robson S, Ryall EA, Sen D, Roberts
SH, Ward Platt MP. Prospective population based
survey of outcome of pregnancy in diabetic women:
results of the Northern Diabetic Pregnancy Audit,
1994. BMJ 1997;315:279–81.
131. Confidential Enquiry into Maternal and Child
Health (CEMACH). Diabetes in Pregnancy: Are we
providing the best care? Findings of a National Enquiry,
February 2007. URL: www.cemach.org.uk/Final%20
CEMACH%20report%20070207.pdf.
132. Lapolla A, Dalfra MG, Masin M, Bruttomesso
D, Piva I, Crepaldi C, et al. Analysis of outcome
of pregnancy in type 1 diabetics treated with
insulin pump or conventional insulin therapy. Acta
Diabetologica 2003;40:143–9.
133. Gimenez M, Conget I, Nicolau J, Pericot A, Levy
I. Outcome of pregnancy in women with type
1 diabetes intensively treated with continuous
subcutaneous insulin infusion or conventional
therapy. A case-control study. Acta Diabetologica
2007;44:34–7.
134. Chen R, Yogev Y, Weissman-Brenner A,
Haroush AB, Hod M. Level of glycemic control
and pregnancy outcome in type-1 diabetes: A
comparison between multiple daily injections (MDI)
and continuous subcutaneous insulin infusions
(CSII). Am J Obstet Gynecol 2006;195:S132.
135. Cheng Y, Block-Kurbisch I, Inturrisi M, Ustinov
A, Caughey A. Insulin pump compared to injected
insulin in pregnant women with type 1 diabetes. Am
J Obstet Gynecol 2006;195:S125.
136. Kinsley BT, Al-Agha R, Murray S, Firth R.
Continuous subcutaneous insulin infusion (CSII)
versus multiple daily injection regimes using soluble
human insulin or rapid acting insulin analoque
in T1DM in pregnancy (T1DMP). Diabetologia
2005;48:A314–15.
137. Jimenez M, Hernaez R, Conget I, Alonso A, Yago
G, Pericot A, et al. Metabolic control, maternal and
perinatal outcomes in type 1 diabetic pregnancies
intensively treated with conventional insulin therapy
vs. continuous subcutaneous insulin infusion.
Diabetologia 2005;48:A315.
138. Pickup JC, Kidd J, Burmiston S, Yemane N.
Effectiveness of continuous subcutaneous insulin
infusion in hypoglycaemia-prone type 1 diabetes.
Pract Diabetes Int 2005;22:10–14.
139. Pickup JC, Kidd J, Burmiston S, Yemane N.
Determinants of glycaemic control in type 1
diabetes during intensified therapy with multiple
daily insulin injections or continuous subcutaneous
insulin infusion: importance of blood glucose
variability. Diabetes/Metab Res Rev 2006;22:232–7.
140. Rodrigues IA, Reid HA, Ismail K, Amiel SA.
Indications and efficacy of continuous subcutaneous
insulin infusion (CSII) therapy in Type 1 diabetes
mellitus: a clinical audit in a specialist service. Diabet
Med 2005;22:842–9.
141. Bruttomesso D, Costa S, Crazzolara D, Di Bartolo P,
Girelli A, Tiengo A, et al. Continuous subcutaneous
insulin infusion (CSII) in Italy. Diabetes Res Clin Pract
2006;74(Suppl. 2):S130–4.
142. Norgaard K. A nationwide study of continuous
subcutaneous insulin infusion (CSII) in Denmark.
Diabet Med 2003;20:307–11.
143. Radermecker RP, Legrand DA, Scheen AJ.
Continuous subcutaneous insulin therapy in type 1
diabetic patients: retrospective study of about 500
patient-years. Diabetologia 2005;48:A328.
144. D’Annunzio G, Minuto N, Serfaino M, Minicucci
L, Pistorio A, Lorini R. Continuous subcutaneous
insulin infusion (CSII) in young patients with type
1 diabetes mellitus (T1DM): A follow-up study.
Diabetes 2005;54:A665.
145. Linkeschova R, Raoul M, Bott U, Berger M, Spraul
M. Less severe hypoglycaemia, better metabolic
control, and improved quality of life in Type 1
diabetes mellitus with continuous subcutaneous
insulin infusion (CSII) therapy; an observational
study of 100 consecutive patients followed for a
mean of 2 years. Diabet Med 2002;19:746–51.
146. Reda E, Von Reitzenstein A, Dunn P. Metabolic
control with insulin pump therapy: the Waikato
experience. New Zealand Med J 2007;120:U2401.
147. Nimri R, Weintrob N, Benzaquen H, Ofan R,
Fayman G, Phillip M. Insulin pump therapy in
youth with type 1 diabetes: a retrospective paired
study. Pediatrics 2006;117:2126–31.
148. Jankovec Z, Lacigova S, Zourek M, Krcma M,
Rusavy Z. Long-term results of continuous
subcutaneous insulin infusion (CSII) treatment in
the Czech Republic. Diabetes 2005;54:A494.
149. Alemzadeh R, Ellis JN, Holzum MK, Parton
EA, Wyatt DT. Beneficial effects of continuous
subcutaneous insulin infusion and flexible multiple
daily insulin regimen using insulin glargine in type
1 diabetes. Pediatrics 2004;114:e91–5.
150. Hanas R, Adolfsson P. Insulin pumps in pediatric
routine care improve long-term metabolic control
without increasing the risk of hypoglycemia. Pediatr
Diabetes 2006;7:25–31.
151. Kordonouri O, Hartmann R, Lauterborn R,
Barnekow C, Hoeffe J, Deiss D. Age-specific
advantages of continuous subcutaneous insulin
infusion as compared with multiple daily
injections in pediatric patients: one-year follow-up
comparison by matched-pair analysis. Diabetes Care
2006;29:133–4.
152. McMahon SK, Airey FL, Marangou DA, McElwee
KJ, Carne CL, Clarey AJ, et al. Insulin pump
therapy in children and adolescents: improvements
in key parameters of diabetes management
including quality of life. Diabet Med 2005;22:92–6.
153. Saha M-T, Huupponen T, Knip M, Juuti M,
Komulainen J. Continuous subcutaneous insulin
infusion in the treatment of children and
adolescents with type 1 diabetes mellitus. J Pediatr
Endocrinol Metab 2002;15:1005–10.
154. Willi SM, Planton J, Egede L, Schwarz S. Benefits
of continuous subcutaneous insulin infusion
in children with type 1 diabetes. J Pediatr
2003;143:796–801.
155. Wood JR, Moreland EC, Volkening LK, Svoren
BM, Butler DA, Laffel LM. Durability of insulin
pump use in pediatric patients with type 1 diabetes.
Diabetes Care 2006;29:2355–60.
156. Weinzimer SA, Ahern JH, Doyle EA, Vincent MR,
Dziura J, Steffen AT, et al. Persistence of benefits
of continuous subcutaneous insulin infusion
in very young children with type 1 diabetes: a
follow-up report. [Erratum appears in Pediatrics
2005;115:518.] Pediatrics 2004;114:1601–5.
157. Conrad SC, McGrath MT, Gitelman SE. Transition
from multiple daily injections to continuous
subcutaneous insulin infusion in type 1 diabetes
mellitus. J Pediatr 2002;140:235–40.
158. Plotnick LP, Clark LM, Brancati FL, Erlinger T.
Safety and effectiveness of insulin pump therapy
in children and adolescents with type 1 diabetes.
Diabetes Care 2003;26:1142–6.
159. Raile K, Noelle V, Landgraf R, Schwarz HP. Weight
in adolescents with type 1 diabetes mellitus during
continuous subcutaneous insulin infusion (CSII)
therapy. J Pediatr Endocrinol 2002;15:607–12.
160. Sulli N, Shashaj B. Continuous subcutaneous
insulin infusion in children and adolescents with
diabetes mellitus: decreased HbA1c with low risk of
hypoglycemia. J Pediatr Endocrinol 2003;16:393–9.
161. Fahlen M, Eliasson B, Oden A. Optimization
of basal insulin delivery in type 1 diabetes: a
retrospective study on the use of continuous
subcutaneous insulin infusion and insulin glargine.
Diabet Med 2005;22:382–6.
162. Lepore G, Dodesini AR, Nosari I, Trevisan R.
Effect of continuous subcutaneous insulin infusion
vs multiple daily insulin injection with glargine as
basal insulin: an open parallel long-term study.
Diabetes Nutr Metab Clin Exp 2004;17:84–9.
163. Siegel-Czarkowski L, Herold KC, Goland RS.
Continuous subcutaneous insulin infusion in
older patients with type 1 diabetes. Diabetes Care
2004;27:3022–3.
164. Litton J, Rice A, Friedman N, Oden J, Lee MM,
Freemark M. Insulin pump therapy in toddlers and
preschool children with type 1 diabetes mellitus. J
Pediatr 2002;141:490–5.
165. Berhe T, Postellon D, Wilson B, Stone R. Feasibility
and safety of insulin pump therapy in children aged
2 to 7 years with type 1 diabetes: a retrospective
study. Pediatrics 2006;117:2132–7.
166. Ahern JA, Boland EA, Doane R, Ahern JJ, Rose
P, Vincent M, et al. Insulin pump therapy in
pediatrics: a therapeutic alternative to safely lower
HbA1c levels across all age groups. Pediatric Diabetes
2002;3:10–15.
167. Garcia-Garcia E, Galera R, Aguilera P, Cara
G, Bonillo A. Long-term use of continuous
subcutaneous insulin infusion compared with
multiple daily injections of glargine in pediatric
patients. J Pediatr Endocrinol 2007;20:37–40.
168. Schiaffini R, Ciampalini P, Spera S, Cappa M, Crino
A. An observational study comparing continuous
subcutaneous insulin infusion (CSII) and insulin
glargine in children with type 1 diabetes. Diabetes
Metab Res Rev 2005;21:347–52.
169. Cersosimo E, Jornsay D, Arce C, Rieff M, Feldman
E, Defronzo R. Improved clinical outcomes with
intensive insulin pump therapy in type 1 diabetes.
Diabetes 2002;51:A128.
170. Hunger-Dathe W, Braun A, Muller UA, Schiel R,
Femerling M, Risse A. Insulin pump therapy in
patients with type 1 diabetes mellitus: results of the
Nationwide Quality Circle in Germany (ASD) 1999–
2000. Exp Clin Endocrinol Diabetes 2003;111:428–34.
171. Juliusson PB, Graue M, Wentzel-Larsen T, Sovik
O. The impact of continuous subcutaneous insulin
infusion on health-related quality of life in children
and adolescents with type 1 diabetes. Acta Paediatrica
2006;95:1481–7.
172. Liberatore JR, Perlman K, Buccino J, Artiles-Sisk
A, Daneman D. Continuous subcutaneous insulin
infusion pump treatment in children with type
1 diabetes mellitus. J Pediatr Endocrinol Metab
2004;17:223–6.
173. Mack-Fogg JE, Orlowski CC, Jospe N. Continuous
subcutaneous insulin infusion in toddlers and
children with type 1 diabetes mellitus is safe and
effective. Pediatr Diabetes 2005;6:17–21.
174. Shehadeh N, Battelino T, Galatzer A, Naveh T,
Hadash A, de Vries L, et al. Insulin pump therapy
for 1–6 year old children with type 1 diabetes. Isr
Med Assoc J (IMAJ) 2004;6:284–6.
175. Garg SK, Walker AJ, Hoff HK, D’Souza AO, Gottlieb
PA, Chase HP. Glycemic parameters with multiple
daily injections using insulin glargine versus insulin
pump. Diabetes Technol Ther 2004;6:9–15.
176. Ronsin O, Jannot-Lamotte MF, Vague P, Lassman-
Vague V. Factors related to CSII compliance. Diabetes
Metab 2005;31:90–5.
177. Sucunza A, Ubeda J, Martinez C, Martinez MJ,
Abraldes N, Corcoy R, et al. Unsuccessful outcome
of insulin pump treatment is not predictable by
clinical characteristics. Diabetes 2005;54:A105.
178. Mednick L, Cogen FR, Streisand R. Satisfaction and
quality of life in children with type 1 diabetes and
their parents following transition to insulin pump
therapy. Child Health Care 2004;33:169–83.
179. Simmons JH, McFann KK, Brown AC, Rewers A,
Cruz E, Klingensmith GJ. Achieving pediatric ADA
HbA1c goals: insulin pump therapy vs injection
therapy. Diabetes 2006;55:A413.
180. Sullivan-Bolyai S, Knafl K, Tamborlane W, Grey M.
Parents’ reflections on managing their children’s
diabetes with insulin pumps. J Nurs Scholarsh
2004;36:316–23.
181. Toni S, Reali MF, Fasulo A, Festini P, Medici A,
Martinucci ME. The use of insulin pumps improves
the metabolic control in children and adolescents
with type 1 diabetes. [Erratum appears in Arch Dis
Child 2004;89:985 – Note: ‘Festini, F’ corrected to
‘Festini, P’]. Arch Dis Child 2004;89:796–7.
182. Ugrasbul F, Popovic J. BMI changes in pediatric
patients with type diabetes mellitus (T1DM) treated
with continuous subcutaneous insulin infusion
(CSII) therapy. Diabetes 2006;55:A414.
183. Wallach EJ, Iazzetti L, Bowlby DA, Greig F, Patel
A, Hyman S, et al. Sustained improvement in
hemoglobin A1C during long-term treatment with
continuous subcutaneous insulin infusion (CSII) in
pediatric patients. Diabetes 2005;54:A666.
184. Alemzadeh R, Palma-Sisto P, Parton E, Holzum
M, Kichler J. Insulin pump therapy attenuated
glycemic instability without improving glycemic
control in a one-year study of preschool children
with type 1 diabetes. Diabetes 2006;55:A97.
185. Hanas R, Lindblad B, Lindgren F. Predisposing
conditions and insulin pump use in a 2-year
population study of pediatric ketoacidosis in
Sweden. Diabetes 2005;54:A455.
186. Conwell LS, Pope E, Artiles AM, Mohanta A,
Daneman A, Daneman D. Dermatological
Complications of Continuous Subcutaneous Insulin
Infusion in Children and Adolescents. J Pediatr
2008;152:622–8.
187. Kaufman FR, Halvorson M, Kim C,
Pitukcheewanont P. Use of insulin pump therapy at
nighttime only for children 7–10 years of age with
type 1 diabetes. Diabetes Care 2000;23:579–82.
188. Retnakaran R, Hochman J, DeVries JH, Hanaire-
Broutin H, Heine RJ, Melki V, et al. Baseline A1c
determines efficacy of insulin pump therapy:
A pooled analysis of studies of continuous
subcutaneous insulin infusion vs multiple daily
injection regimens using rapid-acting insulin
analogues. Diabetes 2004;53:A114.
189. Hirsch IB, Bode BW, Garg S, Lane WS, Sussman
A, Hu P, et al. Continuous subcutaneous insulin
infusion (CSII) of insulin aspart versus multiple
daily injection of insulin aspart/insulin glargine in
type 1 diabetic patients previously treated with CSII.
Diabetes Care 2005;28:533–8.
190. Barnard KD, Skinner TC. Qualitative study into
quality of life issues surrounding insulin pump use
in type 1 diabetes. Pract Diabetes Int 2007;24:143–8.
191. Barnard KD, Skinner TC. Cross-sectional study into
quality of life issues surrounding insulin pump use
in type 1 diabetes. Pract Diabetes Int 2008;25:194–
200.
192. World Health Organization. WHO Quality of Life-
BREF (WHOQOL-BREF), 2004. URL: www.who.
int/substance_abuse/research_tools/whoqolbref/en/
(accessed 26 February 2009).
193. Weissberg-Benchell J, Antisdel-Lomaglio J, Seshadri
R. Insulin pump therapy: a meta-analysis. Diabetes
Care 2003;26:1079–87.
194. Siebenhofer A, Plank J, Berghold A, Horvath K,
Sawicki PT, Beck P, et al. Meta-analysis of shortacting
insulin analogues in adult patients with
type 1 diabetes: continuous subcutaneous insulin
infusion versus injection therapy. Diabetologia
2004;47:1905.
195. Kapellen TM, Heidtmann B, Bachmann J, Ziegler
R, Grabert M, Holl RW. Indications for insulin
pump therapy in different age groups-an analysis
of 1567 children and adolescents. Diabet Med
2007;24:836–42.
196. Laing SP, Swerdlow AJ, Slater SD, Botha JL,
Burden AC, Waugh NR, et al. The British Diabetic
Association Cohort Study, I: all-cause mortality
in patients with insulin-treated diabetes mellitus.
Diabet Med 1999;16:459–65.
197. Edge JA, Ford-Adams ME, Dunger DB. Causes of
death in children with insulin dependent diabetes
1990–96. Arch Dis Child 1999;81:318–23.
198. Thordarson H, Sovik O. Dead in bed syndrome
in young diabetic patients in Norway. Diabet Med
1995;12:782–7.
199. Tunbridge WM. Factors contributing to deaths of
diabetics under fifty years of age. On behalf of the
Medical Services Study Group and British Diabetic
Association. Lancet 1981;2:569–72.
200. Scuffham P, Carr L. The cost-effectiveness of
continuous subcutaneous insulin infusion compared
with multiple daily injections for the management
of diabetes. Diabet Med 2003;20:586–93.
201. Roze S, Valentine WJ, Zakrzewska KE, Palmer
AJ. Health-economic comparison of continuous
subcutaneous insulin infusion with multiple daily
injection for the treatment of Type 1 diabetes in the
UK. Diabet Med 2005;22:1239–45.
202. Conget D, I, Serrano CD, Rodriguez Barrios JM,
Levy M, I, Castell AC, Roze S. [Cost-utility analysis
of insulin pumps compared to multiple daily doses
of insulin in patients with type 1 diabetes mellitus
in Spain]. [Spanish] Revista Espanola de Salud Publica
2006;80:679–95.
203. Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos
V, Lurati FM, et al. The CORE Diabetes Model:
Projecting long-term clinical outcomes, costs and
cost-effectiveness of interventions in diabetes
mellitus (types 1 and 2) to support clinical and
reimbursement decision-making. Curr Med Res Opin
2004;20(Suppl.1):S5–26.
204. Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos
V, Lurati FM, et al. Validation of the CORE Diabetes
Model against epidemiological and clinical studies.
Curr Med Res Opin 2004;20(Suppl.1):S27–40.
205. Krolewski AS, Warram JH, Christlieb AR, Busick
EJ, Kahn CR. The changing natural history
of nephropathy in type I diabetes. Am J Med
1985;78:785–94.
206. National Diabetes Data Group of the National
Institute of Diabetes and Digestive and Kidney
Diseases. Diabetes in America. 2nd edn. 1995. http://
diabetes.niddk.nih.gov/dm/pubs/america/ (accessed
26 February 2009).
207. National Institute of Diabetes & Digestive & Kidney
Diseases. Epidemiology of Diabetes Interventions
and Complications Study (EDIC), 2008. URL:
www.niddk.nih.gov/patient/edic/edic-public.htm
(accessed 26 February 2009).
208. Mount Hood 4 Modeling Group. Computer
modeling of diabetes and its complications: a report
on the Fourth Mount Hood Challenge Meeting.
Diabetes Care 2007;30:1638–46.
209. Diabetes Control and Complications Trial Research
Group. Effect of intensive diabetes treatment
on the development and progression of longterm
complications in adolescents with insulindependent
diabetes mellitus: Diabetes Control
and Complications Trial. Diabetes Control and
Complications Trial Research Group. J Pediatr
1994;125:177–88.
210. Cryer PE, Davis SN, Shamoon H. Hypoglycemia in
diabetes. Diabetes Care 2003;26:1902–12.
211. National Institute for Health and Clinical
Excellence. Diabetes (type 1 and 2) – inhaled
insulin: Technology Appraisal 113, 2006. http://
guidance.nice.org.uk/TA113 (accessed 26 February
2009).
212. Clarke P, Gray A, Legood R, Briggs A, Holman R.
The impact of diabetes-related complications on
healthcare costs: results from the United Kingdom
Prospective Diabetes Study (UKPDS Study No. 65).
Diabet Med 2003;20:442–50.
213. Clarke P, Gray A, Holman R. Estimating utility
values for health states of type 2 diabetic patients
using the EQ-5D (UKPDS 62). Med Decis Making
2002;22:340–9.
214. Coffey JT, Brandle M, Zhou H, Marriott D, Burke
R, Tabaei BP, et al. Valuing health-related quality of
life in diabetes. Diabetes Care 2002;25:2238–43.
215. Tengs TO, Wallace A. One thousand health-related
quality-of-life estimates. Med Care 2000;38:583–637.
216. Australian Institute of Health and Welfare. The
burden of disease and injury in Australia 2003.
URL: www.aihw.gov.au/publications/hwe/bodaiia03/
bodaiia03.pdf (accessed 6 August 2007).
217. Brown MM, Brown GC, Sharma S. Value-based
medicine and vitreoretinal diseases. Curr Opin
Ophthalmol 2004;15:167–72.
218. Carrington AL, Mawdsley SK, Morley M, Kincey J,
Boulton AJ. Psychological status of diabetic people
with or without lower limb disability. Diabetes Res
Clin Pract 1996;32:19–25.
219. Davis RE, Morrissey M, Peters JR, Wittrup-Jensen
K, Kennedy-Martin T, Currie CJ. Impact of
hypoglycaemia on quality of life and productivity
in type 1 and type 2 diabetes. Curr Med Res Opin
2005;21:1477–83.
220. Lundkvist J, Berne C, Bolinder B, Jonsson L.
The economic and quality of life impact of
hypoglycemia. Eur J Health Econ 2005;6:197–202.
221. Tabaei BP, Shill-Novak J, Brandle M, Burke R,
Kaplan RM, Herman WH. Glycemia and the quality
of well-being in patients with diabetes. Qual Life Res
2004;13:1153–61.
222. Wikblad K, Leksell J, Wibell L. Health-related
quality of life in relation to metabolic control
and late complications in patients with insulin
dependent diabetes mellitus. Qual Life Res
1996;5:123–30.
223. Speight J, Shaw JAM. Does one size really fit all?
Only by considering individual preferences and
priorities will the true impact of insulin pump
therapy on quality of life be determined. Diabet Med
2007;24:693–5.
224. Tsui E, Barnie A, Ross S, Parkes R, Zinman B.
Intensive insulin therapy with insulin lispro: a
randomized trial of continuous subcutaneous
insulin infusion versus multiple daily insulin
injection. Diabetes Care 2001;24:1722–7.
225. Weintrob N, Benzaquen H, Galatzer A, Shalitin S,
Lazar L, Fayman G, et al. Comparison of continuous
subcutaneous insulin infusion and multiple daily
injection regimens in children with type 1 diabetes:
a randomized open crossover trial. Pediatrics
2003;112:559–64.
226. Hoogma RP, Hammond PJ, Gomis R, Kerr D,
Bruttomesso D, Bouter KP, et al. Comparison of the
effects of continuous subcutaneous insulin infusion
(CSII) and NPH-based multiple daily insulin
injections (MDI) on glycaemic control and quality
of life: results of the 5-nations trial. Diabet Med
2006;23:141–7.
227. Hoogma RP, Spijker AJ, Doorn-Scheele M, van
Doorn TT, Michels RP, van Doorn RG, et al.
Quality of life and metabolic control in patients
with diabetes mellitus type 1 treated by continuous
subcutaneous insulin infusion or multiple daily
insulin injections. Neth J Med 2004;62:383–7.
228. Garmo A, Pettersson-Frank B, Ehrenberg A.
Treatment effects and satisfaction in diabetic
patients changing from multiple daily insulin
injections to CSII. Pract Diabetes Int 2004;21:7–12.
229. Sanfield JA, Hegstad M, Hanna RS. Protocol for
outpatient screening and initiation of continuous
subcutaneous insulin infusion therapy: impact on
cost and quality. Diabetes Educ 2002;28:599–607.
230. Bruttomesso D, Pianta A, Crazzolara D, Scaldaferri
E, Lora L, Guarneri G, et al. Continuous
subcutaneous insulin infusion (CSII) in the Veneto
region: efficacy, acceptability and quality of life.
Diabet Med 2002;19:628–34.
231. Barnard KD, Skinner C. Qualitative study into
quality of life benefits associated with insulin pump
use. Diabetes 2006;55:A612.
232. Reid SM, Lawson ML. Comparison of continuous
subcutaneous insulin infusion versus conventional
treatment of Type 1 diabetes with respect to
metabolic control, quality of life and treatment
satisfaction. Pediatric Res 2002;51:A122–3.
233. Galatzer A, Weintrob N, Cohen D, Benzaquen H,
Rimer A, Ofan R, et al. Treatment satisfaction of
type 1 diabetic patients: continuous subcutaneous
insulin infusion versus multiple daily injection.
Diabetes 2002;51:A619.
234. Schweitzer MA, Pieber T, Heinemann L, Grunder
S, Buhr A. Treatment satisfaction and metabolic
control in type 2 patients using CSII: results from
an international observational study. Diabetologia
2006;49:592.
235. Castell C, Palmer AJ, Rodriguez JM, Roze S,
Serrano-Contreras D, Zakrzewska K. Assessing
the efficiency of using Continuous Subcutaneous
Insulin-Infusion (CSII) versus multiple daily
injections (MDI) in Spanish diabetes mellitus type-
1 (DM1) patients. Cost-effectiveness analysis. Value
Health 2005;8:A161.
236. Zakrzewska K, Roze S, Valentine WJ, Palmer
AJ. Health economic comparison of continuous
subcutaneous insulin infusion with multiple daily
injection for the treatment of type 1 diabetes in the
UK. Value Health 2004;7:649–50.
237. Zakrzewska K, Valentine W, Roze S, Palmer A,
Spinas G. Continuous subcutaneous insulin infusion
reduces incidence of diabetes-related complications
when compared with multiple daily injections
for type 1 diabetes treatment: a health economic
analysis in Switzerland. Diabetes 2005;54:A610.
238. Roze S, Palmer AJ, Foos V, Lurati FM. Costeffectiveness
of continuous subcutaneous insulin
infusion versus multiple daily injections for
intensive control of Type 1 diabetes: a French
analysis. Diabetologia 2002;45:A302.
239. Goodall G, Nicklasson L, Zakrzewska K, Foos
V, Valentine WJ, Roze S, et al. Continuous
subcutaneous insulin infusion versus multiple
daily injection of insulin in patients with type 1
diabetes: a long-term health economic analysis in
the Norwegian and Swedish settings. Value Health
2006;9:A227.
240. Nicklasson L, Zakrzewska K, Roze S, Voss V, Attvall
S, Palmer A, et al. Continuous subcutaneous insulin
infusion versus multiple daily injections for type 1
diabetes: a cost-effectiveness analysis for Sweden.
Diabetologia 2006;49:541.
241. Roze S, Palmer AEJ. Long-term cost-effectiveness of
the use of insulin pump compared to multiple daily
injections in type 1 diabetic adolescents. Diabetes
2002;51:A281.
242. Feltbower RG, Campbell FM, Bodansky HJ,
Stephenson CR, McKinney PA. Insulin pump
therapy in childhood diabetes-cost implications for
Primary Care Trusts. Diabet Med 2006;23:86–9.
243. Nuboer R, Bruining GJ. Cost-effectiveness of
continuous subcutaneous insulin infusion (CSII)
in children: illusion or delusion? Pediatr Diabetes
2006;7(Suppl. 4):39–44.
244. Mbowe OT, Buysschaert M, Hermans MP.
Institutional costs of continuous subcutaneous
insulin infusion in type 1 diabetes: an assessment
using Activity-Based Costing (ABC) method. Diabetes
2004;53:A294.
245. Ulahannan T, Myinit NN, Lonnen KF. Making the
case for insulin pump therapy. Pract Diabetes Int
2007;24:252–6.
246. Curtis L, Netten A. Personal Social Services
Research Unit: Unit Costs of Health and Social
Care, 2006. URL: www.pssru.ac.uk/pdf/uc/uc2006/
uc2006.pdf.
247. Ghatnekar O, Persson U, Willis M, Odegaard K.
Cost effectiveness of Becaplermin in the treatment
of diabetic foot ulcers in four European countries.
Pharmacoeconomics 2001;19:767–78.
248. UKPDS 40. Cost effectiveness analysis of improved
blood pressure control in hypertensive patients
with type 2 diabetes: UKPDS 40. UK Prospective
Diabetes Study Group. BMJ 1998;317:720–6.
249. Meads C, Salas C, Roberts T, Moore D, Fry-Smith
A, Hyde C. Clinical effectiveness and cost-utility of
photodynamic therapy for wet age-related macular
degeneration: a systematic review and economic
evaluation. Health Technol Assess 2003;7(9).
250. INPUT. INsulin PUmp Therapy: raising awareness
of insulin pump therapy in the UK. 2008 URL:
www.input.me.uk/ (accessed 26 February 2009).
251. INPUT. Review of NICE Technology Appraisal
No. 57 Insulin Pump Therapy Joint submission
from INPUT and Insulin Pumpers, 8 December
2007. URL: www.nice.org.uk/guidance/index.
jsp?action=download&o=38246 (accessed 26
February 2009).
252. Barnard KD, Speight J, Skinner TC. Quality of life
and impact of continuous subcutaneous insulin
infusion for children and their parents. Pract
Diabetes Int 2008;25:278–84.
253. Children with DIABETES. Children with
DIABETES online community, 2006. URL: www.
childrenwithdiabetes.com (accessed 26 February
2009).
254. Department of Health. National Service Framework
for Children, Young People and Maternity Services:
Medicines for Children and Young People. London:
Department of Health; 2004.
255. NHS Scotland. Scottish Diabetes Framework.
Edinburgh: Scottish Executive; 2002.
256. Khoo E, Miller D, Gazis A. Development and audit
of a CSII service. Diabet Med 2007;24:76.
257. Zisser, H. The impact of insulin pump infusion
set disconnects on short-term glycemic control.
American Diabetes Association, 67th Scientific
Sessions, Chicago, IL, 22–23 June 2007.
258. Pickup J. Personal statement on Continuous
Subcutaneous Insulin Infusion, 2008.
URL: www.nice.org.uk/nicemedia/pdf/
JohnPickupStatement240907CF.pdf (accessed 25
February 2009).
259. Diabetes UK. Postcode lottery on insulin pumps.
2007 URL: www.diabetes.org.uk/en/Get_involved/
Campaigning/Ongoing-campaigns/Postcode-lotteryon-
insulin-pumps/(accessed 26 February 2009).
260. Pickup JC. Are insulin pumps underutilized in type
1 diabetes? Yes. Diabetes Care 2006;29:1449–52.
261. Canadian Agency for Drugs and Technologies
in Health. CEDAC Final Recommendation and
Reconsideration and Reasons for Recommendation:
insulin glargine resubmission, Sanofi-Aventis
Canada, 2006. URL: www.cadth.ca/media/cdr/
complete/cdr_complete_Lantus_Oct25–06.pdf
(accessed 6 August 2007).
262. Farrar D, Tuffnell D, West J. Continuous
subcutaneous insulin infusion versus multiple daily
injections of insulin for pregnant women with
diabetes. Cochrane Database Syst Rev 2007; Issue 2.
263. Roche Diagnostics Ltd. Additional response: clinical
and cost-effectiveness of continuous subcutaneous
infusion for diabetes: updating review, 19
November 2007. URL: www.nice.org.uk/guidance/
index.jsp?action=download&o=38238 (accessed 26
February 2009).
264. Peyrot M, Rubin RR. Patient-Reported Outcomes
(PRO) for an Integrated Real-Time Continuous
Glucose Monitoring/Insulin Pump (RT-CGM/CSII)
System. Abstract no. 0461-P. American Diabetes
Association, 67th Scientific Sessions, Chicago, IL,
22–23 June 2007.
265. Hirsch IB, Bode BW, Abelseth J, Fischer JS,
Kaufman FR, Mastrototaro J, et al. Patient-Reported
Outcomes (PRO) for an Integrated Real-Time
Continuous Glucose Monitoring/Insulin Pump
(RT-CGM/CSII) System. Abstract no. 0090-OR.
American Diabetes Association, 67th Scientific
Sessions, Chicago, IL, 22–23 June 2007.
266. NHS Quality Improvement Scotland. Continuous
glucose monitors in diabetes mellitus – the
Continuous Glucose Monitoring System (CGMS):
Evidence Note 8, 2005. URL: www.nhshealthquality.
org/nhsqis/files/evidence_note8.pdf (accessed 6
August 2007).
267. Hovorka R. Continuous glucose monitoring and
closed-loop systems. Diabet Med 2006;23:1–12.
268. Logtenberg SJJ, Van Ballegooie E, Israel-Bultman
H, van Linde A, Bilo HJG. Glycaemic control,
health status and treatment satisfaction in subjects
with diabetes mellitus treated with continuous
intraperitoneal insulin infusion (CIPII). A single
centre experience. Diabetologia 2006;49:592–3.
269. Renard E, Schaepelynck-Belicar P. Implantable
insulin pumps. A position statement about their
clinical use. Diabetes Metab 2007;33:158–66.
270. Bismuth E, Svoren B, Volkening LK, Butler DA,
Laffel LM. Impact of Insulin Pump Therapy and
Blood [beta]-OHB Ketone Monitoring on Glycemic
Outcomes in Youth with Type 1 Diabetes (T1D).
Abstract no. 1920-P. American Diabetes Association,
67th Scientific Sessions, Chicago, IL, 22–23 June
2007.
271. Brinchmann-Hansen O, Dahl-Jorgensen K, Hanssen
KF, Sandvik L. The response of diabetic retinopathy
to 41 months of multiple insulin injections, insulin
pumps, and conventional insulin therapy. Arch
Ophthalmol 1988;106:1242–6.
272. Chiasson JL, Ducros F, Poliquin HM, Lopez D,
Lecavalier L, Hamet P. Continuous subcutaneous
insulin infusion (Mill-Hill Infuser) versus multiple
injections (Medi-Jector) in the treatment of insulindependent
diabetes mellitus and the effect of
metabolic control on microangiopathy. Diabetes Care
1984;7:331–7.
273. Hanaire-Broutin H, Melki V, Bessieres-Lacombe S,
Tauber JP. Comparison of continuous subcutaneous
insulin infusion and multiple daily injection
regimens using insulin lispro in type 1 diabetic
patients on intensified treatment: a randomized
study. The Study Group for the Development
of Pump Therapy in Diabetes. Diabetes Care
2000;23:1232–5.
274. Home PD, Capaldo B, Burrin JM, Worth R,
Alberti KG. A crossover comparison of continuous
subcutaneous insulin infusion (CSII) against
multiple insulin injections in insulin-dependent
diabetic subjects: improved control with CSII.
Diabetes Care 1982;5:466–71.
275. Nathan DM, Lou PAJ. Intensive conventional and
insulin pump therapy in adult type 1 diabetes. A
crossover study. Ann Intern Med 1982;97:31–6.
276. Saurbrey N, Arnold-Larsen S, Moller-Jensen B,
Kuhl C. Comparison of continuous subcutaneous
insulin infusion with multiple insulin injections
using the NovoPen. Diabet Med 1988;5:150–3.
277. Schiffrin A, Belmonte MM. Comparison between
continuous subcutaneous insulin infusion and
multiple injection of insulin. A one-year prospective
study. Diabetes 1982;31:255–64.
278. Tsui E, Barnie A, Ross S, Parkes R, Zinman B.
Intensive insulin therapy with insulin lispro: a
randomized trial of continuous subcutaneous
insulin infusion versus multiple daily insulin
injection. Diabetes Care 2001;24:1722–7.
279. Haakens K, Hanssen KF, Dahl-Jorgensen K,
Vaaler S, Aagenaes O, Mosand R. Continuous
subcutaneous insulin infusion (CSII), multiple
injections (MI) and conventional insulin therapy
(CT) in self-selecting insulin-dependent diabetic
patients. A comparison of metabolic control, acute
complications and patient preferences. J Intern Med
1990;228:457–64.
280. Schmitz A, Christiansen JS, Christensen CK,
Hermansen K, Mogensen CE. Effect of pump versus
pen treatment on glycaemic control and kidney
function in long-term uncomplicated insulindependent
diabetes mellitus (IDDM). Dan Med Bull
1989;36:176–8.
281. Ziegler D, Dannehl K, Koschinsky T, Toeller M,
Gries FA. Comparison of continuous subcutaneous insulin infusion and intensified conventional
therapy in the treatment of type I diabetes: a two
year randomized study. Diabetes Nutr Metab Clin Exp
1990;3:203–13.
282. Bode BW, Steed RD, Davidson PC. Reduction in
severe hypoglycemia with long-term continuous
subcutaneous insulin infusion in type I diabetes.
Diabetes Care 1996;19:324–7.
283. Nosadini R, Velussi M, Fioretto P, Doria A, Avogaro
A, Trevisan R, et al. Frequency of hypoglycaemic
and hyperglycaemic–ketotic episodes during
conventional and subcutaneous continuous insulin
infusion therapy in IDDM. Diabetes Nutr Metab
1988;1:289–96.
284. Melki V, Renard E, Lassmann-Vague V, Boivin S,
Guerci B, Hanaire-Broutin H, et al. Improvement of
HbA1c and blood glucose stability in IDDM patients
treated with lispro insulin analog in external pumps.
Diabetes Care 1998;21:977–82.
285. Raskin P, Holcombe JH, Tamborlane WV, Malone
JI, Strowig S, Ahern JA, et al. A comparison of
insulin lispro and buffered regular human insulin
administered via continuous subcutaneous insulin
infusion pump. J Diabetes Complications 2001;15:295–
300.
286. Renner R, Pfutzner A, Trautmann M, Harzer O,
Sauter K, Landgraf R. Use of insulin lispro in
continuous subcutaneous insulin infusion treatment.
Results of a multicenter trial. German Humalog-
CSII Study Group. Diabetes Care 1999;22:784–8.
287. Schmauss S, Konig A, Landgraf R. Human insulin
analogue [LYS(B28), PRO(B29)]: the ideal pump
insulin? Diabet Med 1998;15:247–9.
288. Zinman B, Tildesley H, Chiasson JL, Tsui E, Strack
T. Insulin lispro in CSII: results of a doubleblind
crossover study. Diabetes 1997;46:440–3.
289. Bode B, Weinstein R, Bell D, McGill J, Nadeau
D, Raskin P, et al. Comparison of insulin aspart
with buffered regular insulin and insulin lispro
in continuous subcutaneous insulin infusion: a
randomized study in type 1 diabetes. Diabetes Care
2002;25:439–44.
290. Britten N, Jones R, Murphy E, Stacy R. Qualitative
research methods in general practice and primary
care. Fam Pract 1995;12:104–14.
291. Pope C, Mays N. Reaching the parts other methods
cannot reach: an introduction to qualitative
methods in health and health services research. BMJ
1995;311:42–5.
292. Mason J. Qualitative researching. London: Thousand
Oaks; 2002.
293. Creswel JW. Qualitative inquiry and research design:
choosing among five approaches. London: Sage
Publications; 2003.
294. van der Heijden K. Scenarios: the art of strategic
conversation. Chichester: John Wiley; 2005.
295. Glaser NS, Strauss A. Discovery of grounded theory.
Chicago, IL: Aldine; 1967.
296. Strauss A, Corbin J. Basics of qualitative research:
grounded theory procedures and techniques. London:
Sage; 1990.
297. Mechanic D. Public trust and initiatives for new
health care partnerships. Milbank Q 1998;76:281–
302.
298. Brownlie J, Greene A, Howson A (editors).
Researching trust and health. New York, NY:
Routledge; 2008.